Jonathan R. Dry
YOU?
Author Swipe
View article: Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapy
Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapy Open
Immune checkpoint blockade (ICB) has revolutionised cancer therapy, yet resistance — both primary and acquired — remains a significant obstacle, affecting the majority of patients. Here, we leveraged a large-scale, real-world clinicogenomi…
View article: Pan-Cancer Analysis in the Real-World Setting Uncovers Immunogenomic Drivers of Acquired Resistance Post-Immunotherapy
Pan-Cancer Analysis in the Real-World Setting Uncovers Immunogenomic Drivers of Acquired Resistance Post-Immunotherapy Open
View article: Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion Open
Inhibition of CDK4/6 kinases has led to improved outcomes in breast cancer. Nevertheless, only a minority of patients experience long-term disease control. Using a large, clinically annotated cohort of patients with metastatic hormone rece…
View article: Author Correction: Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors
Author Correction: Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors Open
View article: Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models Open
A video describing PDX mice, minimal information, and why minimal information is needed in the PDX research field.
View article: S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models Open
A figure showing the process of generating and using PDX models.
View article: Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models Open
A video describing PDX mice, minimal information, and why minimal information is needed in the PDX research field.
View article: S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models Open
A figure showing the process of generating and using PDX models.
View article: Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models Open
Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug response and resistance, and tailoring chemotherapeutic approaches for individual patie…
View article: Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models Open
A video describing PDX mice, minimal information, and why minimal information is needed in the PDX research field.
View article: Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models Open
A video describing PDX mice, minimal information, and why minimal information is needed in the PDX research field.
View article: S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models Open
A figure showing the process of generating and using PDX models.
View article: S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models Open
A figure showing the process of generating and using PDX models.
View article: Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors
Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors Open
View article: Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling Open
The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. He…
View article: Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models Open
Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug response and resistance, and tailoring chemotherapeutic approaches for individual patie…
View article: Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA Damage Response inhibitors
Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA Damage Response inhibitors Open
Combination therapy is well established as a key intervention strategy for cancer treatment, with the potential to overcome monotherapy resistance and deliver a more durable efficacy. However, given the scale of unexplored potential target…
View article: 620 Multimodal real world data reveals immunogenomic drivers of acquired and primary resistance to immune checkpoint blockade
620 Multimodal real world data reveals immunogenomic drivers of acquired and primary resistance to immune checkpoint blockade Open
Background Why some patients fail or have short lived response to immune checkpoint blockade (ICB) immunotherapy remains largely unknown. While baseline molecular assessments have provided clues to prognostic factors, insights into resista…
View article: Data from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Data from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies Open
The bromodomain and extraterminal (BET) protein BRD4 regulates gene expression via recruitment of transcriptional regulatory complexes to acetylated chromatin. Pharmacological targeting of BRD4 bromodomains by small molecule inhibitors has…
View article: supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Differential gene expression and statistical analysis of cell lines treated with AZD4547 or DMSO over time
View article: Data from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
Data from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
The challenge of developing effective pharmacodynamic biomarkers for preclinical and clinical testing of FGFR signaling inhibition is significant. Assays that rely on the measurement of phospho-protein epitopes can be limited by the availa…
View article: supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
55 FGFR2 modified dynamic biomarker after treatment by AZD4547
View article: Supplementary Table 1 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Supplementary Table 1 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies Open
Cell line authentication information
View article: Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Supplementary figures S1: volcano plot of insensitive cell lines treated by AZD4547 S2:Immunohistochemistry of p-S6 and p-ERK tissue sections from xenograft treated with AZD4547 S3:FGFR pathway modulation in xenograft models treated with A…
View article: supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Cell line panel used to identify AZD4547 dynamic transcript biomarkers.
View article: supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Statistical analysis of gene modulation between FGFR1, 2 and 3 dysregulated cell lines.
View article: Supplementary Table 2 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Supplementary Table 2 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies Open
Differentially expressed genes with AZD5153 treatment
View article: supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Statistical analysis of gene modulation between FGFR1, 2 and 3 dysregulated cell lines.
View article: supplementary Table 6 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 6 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Differential gene expression and two statistical analysis of ANC3A xenograft after treatment by AZD4547 and/or AZD5363 compared to vehicle group, and Combination group compared to singled agent.
View article: supplementary Table 3 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547
supplementary Table 3 from Identification of Pharmacodynamic Transcript Biomarkers in Response to <i>FGFR</i> Inhibition by AZD4547 Open
Gene symbol and primer ID used for targeted profiling on Fluidigm arrays